AVTX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
-100.0%
59.0K
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
-100.0%
59.0K
0
Operating Expenses
23.4M
-25.8%
31.5M
+50.8%
20.9M
+5.6%
19.8M
+3.1%
19.2M
R&D
15.0M
-35.8%
23.4M
+66.7%
14.0M
+5.9%
13.3M
-2.6%
13.6M
SG&A
8.4M
+3.1%
8.1M
+18.2%
6.9M
+4.9%
6.5M
+17.2%
5.6M
Operating Income
-23397000
+25.8%
-31517000
-50.8%
-20901000
-5.9%
-19742000
-2.8%
-19198000
EBITDA
-23379000
+25.8%
-31500000
-50.8%
-20884000
-5.9%
-19726000
-3.1%
-19139000
Net Income
-18945000
+47.9%
-36358000
-85.2%
-19630000
-43.1%
-13720000
+55.2%
-30625000
EPS (Basic)
$-0.34
+59.0%
$-0.83
+15.3%
$-0.98
-30.7%
$-0.75
+65.8%
$-2.19
EPS (Diluted)
$-0.34
+59.0%
$-0.83
+15.3%
$-0.98
-30.7%
$-0.75
+65.8%
$-2.19
Shares (Diluted)
55.1M
+26.3%
43.6M
+116.9%
20.1M
+10.0%
18.3M
+30.5%
14.0M
Avalo Therapeutics (AVTX) — Financials